IP Library Granted Patent US 9,938,355
Granted Patent B2
US 9,938,355 · App. 14/794,273 · Granted Apr 10, 2018

Antibodies to argininosuccinate synthase and related methods

Inventors: Wei He (San Diego, CA); Yunyun Guo (Shanghai, CN); Bor-Wen Wu (San Diego, CA)
Assignee: TDW Group
C07K16/40A61K38/45A61K38/50A61K38/51C12N9/78C12Y207/00C12Y207/03003C12Y401/01019G01N33/573G01N33/57496C07K2317/20C07K2317/565C07K2317/76C12Y305/03006G01N2333/9015G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,938,355
App. No.
14/794,273
Granted
Apr 10, 2018
Kind
B2
Abstract

Antibodies, and antigen-binding fragments, which specifically bind to argininosuccinate synthase, and related compositions, kits, and methods of use, which are useful as companion diagnostics to identify suitable subjects for arginine deprivation or depletion therapies such as ADI-PEG 20 and other arginine deiminase (ADI) polypeptide-based therapies.

Claims (22)

1. An isolated antibody, or antigen-binding fragment thereof, which specifically binds to a human argininosuccinate synthase polypeptide and comprises a heavy chain variable region (V H ) sequence that comprises complementary determining region V H CDR1, V H CDR2, and V H CDR3 sequences set forth respectively in SEQ ID NOs:7, 8, and 9, and a light chain variable region (V L ) sequence that comprises complementary determining region V L CDR1, V L CDR2, and V L CDR3 sequences set forth respectively in SEQ ID NOs:10, 11, and 12.

2. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , where the V H sequence is at least 90% identical to SEQ ID NO:1.

3. The isolated antibody, or antigen-binding fragment thereof, of claim 1 or 2 , where the V L sequence is at least 90% identical to SEQ ID NO:3.

4. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , where the V H sequence comprises SEQ ID NO:1 and the V L sequence comprises SEQ ID NO:3.

5. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , where the antibody is a whole antibody.

6. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , where the antibody is a monoclonal antibody.

7. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , which is selected from of a single chain antibody, a Fab or a Fab' fragment, F(ab')2 fragment, an ScFv, a univalent antibody lacking a hinge region, and a minibody.

8. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , where the antibody comprises a mouse or human IgG Fc domain, optionally a IgG1 or IgG2A Fc domain.

9. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , where the antibody is a mouse monoclonal antibody of subtype IgG1 or IgG2A.

10. The isolated antibody, or antigen-binding fragment thereof, of claim 1 , comprising a covalently-attached detectable entity.

11. The isolated antibody, or antigen-binding fragment thereof, of claim 10 , where the detectable entity is a fluorophore/fluorescent dye, an iodine-based label, a radioisotope, or a nanoparticle.

12. A composition, comprising an antibody of claim 1 , and a suitable carrier.

13. A method of determining an amount of human argininosuccinate synthase polypeptide in a biological sample, comprising (a) obtaining or receiving a biological sample, optionally from a subject, (b) contacting the biological sample with an antibody, or antigen-binding fragment thereof, of claim 1 , and (c) measuring the amount of the antibody, or antigen-binding fragment thereof, in the sample, where the amount of the antibody, or antigen-binding fragment thereof, determines the amount of the argininosuccinate synthase polypeptide in the sample.

14. A kit, comprising an isolated antibody of claim 1 .

15. The kit of claim 14 , comprising instructions for using the antibody according to a method of claim 13 .

16. The kit of claim 14 , further comprising materials and/or instructions for an immunohistochemistry (IHC) assay.

17. The kit of claim 14 , further comprising materials and/or instructions for an enzyme-linked immunosorbent assay (ELISA), optionally where the antibody is attached to a solid substrate for performing an ELISA.

18. The kit of claim 14 , comprising instructions for using the antibody to identify a subject for arginine deprivation therapy.

19. The kit of claim 17 , where the arginine deprivation therapy is an arginine depletion agent, optionally ADI-PEG 20.

20. The kit of claim 14 , further comprising at least one arginine depletion agent.

21. The kit of claim 20 , where the arginine depletion agent is selected from an arginine deiminase (ADI) polypeptide, an arginase polypeptide, an arginine decarboxylase polypeptide, and an arginine kinase polypeptide.

22. The kit of claim 21 , where the ADI polypeptide is ADI-PEG 20.

Assignments (2)
MERGER Recorded Mar 13, 2025
From: TDW GROUP
To: POLARIS GROUP
Reel/Frame 070502/0383 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 17, 2015
From: HE, WEI; GUO, YUNYUN; WU, BOR-WEN
To: TDW GROUP
Reel/Frame 036591/0122 →
Continuity (2)
Provisional Application 62022066 · Jul 8, 2014
Related Publication 20160009821A1 · Jan 14, 2016